Annual Current Liabilities
$17.96 M
-$1.02 M-5.38%
December 31, 2023
Summary
- As of February 7, 2025, LCTX annual total current liabilities is $17.96 million, with the most recent change of -$1.02 million (-5.38%) on December 31, 2023.
- During the last 3 years, LCTX annual current liabilities has risen by +$10.19 million (+131.18%).
- LCTX annual current liabilities is now -61.88% below its all-time high of $47.12 million, reached on December 31, 2021.
Performance
LCTX Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$13.86 M
-$1.41 M-9.24%
September 30, 2024
Summary
- As of February 7, 2025, LCTX quarterly total current liabilities is $13.86 million, with the most recent change of -$1.41 million (-9.24%) on September 30, 2024.
- Over the past year, LCTX quarterly current liabilities has dropped by -$2.02 million (-12.70%).
- LCTX quarterly current liabilities is now -70.57% below its all-time high of $47.12 million, reached on December 31, 2021.
Performance
LCTX Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
LCTX Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -5.4% | -12.7% |
| 3 y3 years | +131.2% | -39.0% |
| 5 y5 years | +163.7% | +109.4% |
LCTX Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -61.9% | at low | -70.6% | at low |
| 5 y | 5-year | -61.9% | +176.6% | -70.6% | +113.5% |
| alltime | all time | -61.9% | -100.0% | -70.6% | -100.0% |
Lineage Cell Therapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $13.86 M(-9.2%) |
| Jun 2024 | - | $15.28 M(-9.6%) |
| Mar 2024 | - | $16.89 M(-6.0%) |
| Dec 2023 | $17.96 M(-5.4%) | $17.96 M(+13.1%) |
| Sep 2023 | - | $15.88 M(-1.1%) |
| Jun 2023 | - | $16.05 M(-6.8%) |
| Mar 2023 | - | $17.23 M(-9.3%) |
| Dec 2022 | $18.98 M(-59.7%) | $18.98 M(-16.5%) |
| Sep 2022 | - | $22.74 M(-9.4%) |
| Jun 2022 | - | $25.09 M(+2.0%) |
| Mar 2022 | - | $24.59 M(-47.8%) |
| Dec 2021 | $47.12 M(+506.5%) | $47.12 M(+436.0%) |
| Sep 2021 | - | $8.79 M(+29.9%) |
| Jun 2021 | - | $6.77 M(+2.2%) |
| Mar 2021 | - | $6.62 M(-14.8%) |
| Dec 2020 | $7.77 M(+19.6%) | $7.77 M(+0.2%) |
| Sep 2020 | - | $7.75 M(+3.1%) |
| Jun 2020 | - | $7.52 M(+7.9%) |
| Mar 2020 | - | $6.97 M(+7.3%) |
| Dec 2019 | $6.49 M(-4.7%) | $6.49 M(+5.4%) |
| Sep 2019 | - | $6.16 M(-21.6%) |
| Jun 2019 | - | $7.86 M(-9.9%) |
| Mar 2019 | - | $8.72 M(+28.1%) |
| Dec 2018 | $6.81 M(-1.0%) | $6.81 M(+51.3%) |
| Sep 2018 | - | $4.50 M(-22.9%) |
| Jun 2018 | - | $5.84 M(+0.6%) |
| Mar 2018 | - | $5.81 M(-15.5%) |
| Dec 2017 | $6.88 M(-22.3%) | $6.88 M(+14.4%) |
| Sep 2017 | - | $6.01 M(-55.6%) |
| Jun 2017 | - | $13.53 M(+53.4%) |
| Mar 2017 | - | $8.82 M(-0.3%) |
| Dec 2016 | $8.85 M(-29.0%) | $8.85 M(+6.1%) |
| Sep 2016 | - | $8.34 M(+12.6%) |
| Jun 2016 | - | $7.40 M(-45.8%) |
| Mar 2016 | - | $13.67 M(+9.7%) |
| Dec 2015 | $12.46 M(+76.3%) | $12.46 M(+20.6%) |
| Sep 2015 | - | $10.34 M(+12.4%) |
| Jun 2015 | - | $9.19 M(+12.1%) |
| Mar 2015 | - | $8.20 M(+16.0%) |
| Dec 2014 | $7.07 M(+1.6%) | $7.07 M(+22.1%) |
| Sep 2014 | - | $5.79 M(+14.2%) |
| Jun 2014 | - | $5.07 M(-9.8%) |
| Mar 2014 | - | $5.62 M(-19.2%) |
| Dec 2013 | $6.96 M(+58.5%) | $6.96 M(+51.3%) |
| Sep 2013 | - | $4.60 M(+3.7%) |
| Jun 2013 | - | $4.43 M(+3.2%) |
| Mar 2013 | - | $4.30 M(-2.2%) |
| Dec 2012 | $4.39 M(+39.5%) | $4.39 M(+70.7%) |
| Sep 2012 | - | $2.57 M(-13.1%) |
| Jun 2012 | - | $2.96 M(+50.7%) |
| Mar 2012 | - | $1.97 M(-37.5%) |
| Dec 2011 | $3.15 M(+26.9%) | $3.15 M(+15.6%) |
| Sep 2011 | - | $2.72 M(-17.2%) |
| Jun 2011 | - | $3.29 M(+20.5%) |
| Mar 2011 | - | $2.73 M(+10.0%) |
| Dec 2010 | $2.48 M(+113.4%) | $2.48 M(+90.9%) |
| Sep 2010 | - | $1.30 M(-6.0%) |
| Jun 2010 | - | $1.38 M(+22.7%) |
| Mar 2010 | - | $1.13 M(-3.1%) |
| Dec 2009 | $1.16 M(-65.6%) | $1.16 M(+2.2%) |
| Sep 2009 | - | $1.14 M(-73.2%) |
| Jun 2009 | - | $4.25 M(-5.2%) |
| Mar 2009 | - | $4.48 M(+32.7%) |
| Dec 2008 | $3.38 M | $3.38 M(-14.8%) |
| Sep 2008 | - | $3.96 M(+39.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2008 | - | $2.84 M(+30.1%) |
| Mar 2008 | - | $2.18 M(+49.8%) |
| Dec 2007 | $1.46 M(+136.8%) | $1.46 M(+47.1%) |
| Sep 2007 | - | $991.00 K(+6.6%) |
| Jun 2007 | - | $929.50 K(+10.8%) |
| Mar 2007 | - | $839.10 K(+36.3%) |
| Dec 2006 | $615.60 K(-12.9%) | $615.60 K(+23.7%) |
| Sep 2006 | - | $497.70 K(+8.0%) |
| Jun 2006 | - | $461.00 K(+5.3%) |
| Mar 2006 | - | $438.00 K(-38.0%) |
| Dec 2005 | $706.60 K(+40.9%) | $706.60 K(+200.4%) |
| Sep 2005 | - | $235.20 K(-11.8%) |
| Jun 2005 | - | $266.60 K(-0.5%) |
| Mar 2005 | - | $267.90 K(-46.6%) |
| Dec 2004 | $501.50 K(-83.8%) | $501.50 K(+282.5%) |
| Sep 2004 | - | $131.10 K(-11.3%) |
| Jun 2004 | - | $147.80 K(-20.2%) |
| Mar 2004 | - | $185.20 K(-94.0%) |
| Dec 2003 | $3.09 M(+520.8%) | $3.09 M(+14.4%) |
| Sep 2003 | - | $2.70 M(+751.6%) |
| Jun 2003 | - | $317.50 K(-26.0%) |
| Mar 2003 | - | $428.80 K(-14.0%) |
| Dec 2002 | $498.40 K(+61.1%) | $498.40 K(+79.3%) |
| Sep 2002 | - | $278.00 K(-21.8%) |
| Jun 2002 | - | $355.60 K(+87.6%) |
| Mar 2002 | - | $189.60 K(-38.7%) |
| Dec 2001 | $309.30 K(-14.0%) | $309.30 K(-91.0%) |
| Sep 2001 | - | $3.45 M(+315.6%) |
| Jun 2001 | - | $830.60 K(+508.9%) |
| Mar 2001 | - | $136.40 K(-62.1%) |
| Dec 2000 | $359.70 K(-39.6%) | $359.70 K(+215.8%) |
| Sep 2000 | - | $113.90 K(-63.0%) |
| Jun 2000 | - | $308.20 K(+141.9%) |
| Mar 2000 | - | $127.40 K(-78.6%) |
| Dec 1999 | $595.50 K(+48.9%) | $595.50 K(+19.1%) |
| Sep 1999 | - | $500.00 K(+66.7%) |
| Jun 1999 | - | $300.00 K(0.0%) |
| Mar 1999 | - | $300.00 K(-25.0%) |
| Dec 1998 | $400.00 K(-33.3%) | - |
| Sep 1998 | - | $400.00 K(-33.3%) |
| Jun 1998 | - | $600.00 K(-25.0%) |
| Jun 1998 | $600.00 K(-53.8%) | - |
| Mar 1998 | - | $800.00 K(0.0%) |
| Dec 1997 | - | $800.00 K(-33.3%) |
| Sep 1997 | - | $1.20 M(-7.7%) |
| Jun 1997 | $1.30 M(+1200.0%) | $1.30 M(+1200.0%) |
| Mar 1997 | - | $100.00 K(-66.7%) |
| Dec 1996 | - | $300.00 K(+50.0%) |
| Sep 1996 | - | $200.00 K(+100.0%) |
| Jun 1996 | $100.00 K(-66.7%) | $100.00 K(0.0%) |
| Sep 1995 | - | $100.00 K(-66.7%) |
| Jun 1995 | $300.00 K(>+9900.0%) | $300.00 K(+200.0%) |
| Mar 1995 | - | $100.00 K(0.0%) |
| Dec 1994 | - | $100.00 K(0.0%) |
| Sep 1994 | - | $100.00 K(>+9900.0%) |
| Jun 1994 | $0.00(0.0%) | $0.00(-100.0%) |
| Mar 1994 | - | $100.00 K(0.0%) |
| Dec 1993 | - | $100.00 K(>+9900.0%) |
| Sep 1993 | - | $0.00(0.0%) |
| Jun 1993 | $0.00(-100.0%) | $0.00(0.0%) |
| Mar 1993 | - | $0.00(-100.0%) |
| Dec 1992 | - | $100.00 K(0.0%) |
| Sep 1992 | - | $100.00 K(-50.0%) |
| Jun 1992 | $200.00 K | $200.00 K(0.0%) |
| Mar 1992 | - | $200.00 K |
FAQ
- What is Lineage Cell Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual current liabilities year-on-year change?
- What is Lineage Cell Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly current liabilities year-on-year change?
What is Lineage Cell Therapeutics annual total current liabilities?
The current annual current liabilities of LCTX is $17.96 M
What is the all time high annual current liabilities for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual total current liabilities is $47.12 M
What is Lineage Cell Therapeutics annual current liabilities year-on-year change?
Over the past year, LCTX annual total current liabilities has changed by -$1.02 M (-5.38%)
What is Lineage Cell Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of LCTX is $13.86 M
What is the all time high quarterly current liabilities for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly total current liabilities is $47.12 M
What is Lineage Cell Therapeutics quarterly current liabilities year-on-year change?
Over the past year, LCTX quarterly total current liabilities has changed by -$2.02 M (-12.70%)